Chemoresistance in Ovarian Cancer: Prospects for New Drugs
- 1 April 2021
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 21 (6) , 668-678
Abstract
: This review focuses on the conventional treatment, signaling pathways and various reasons for drug resistance with an understanding of novel methods that can lead to effective therapies. Ovarian cancer is amongst the most common gynecological and lethal cancers in women affecting different age groups (20-60). The survival rate is limited to 5 years due to diagnosis in subsequent stages with a reoccurrence of tumor and resistance to chemotherapeutic therapy. The recent clinical trials use the combinatorial treatment of carboplatin and paclitaxel on ovarian cancer after the cytoreduction of the tumor. Predominantly, patients are responsive initially to therapy and later develop metastases due to drug resistance. Chemotherapy also leads to drug resistance causing enormous variations at the cellular level. Multifaceted mechanisms like drug resistance are associated with a number of genes and signaling pathways that process the proliferation of cells. Reasons for resistance include epithelial-mesenchyme, DNA repair activation, autophagy, drug efflux, pathway activation, and so on. Determining the routes on the molecular mechanism that target chemoresistance pathways are necessary for controlling the treatment and understanding efficient drug targets can open light on improving therapeutic outcomes. The most common drug used for ovarian cancer is Cisplatin that activates various chemoresistance pathways, ultimately causing drug resistance. There have been substantial improvements in understanding the mechanisms of cisplatin resistance or chemo sensitizing cisplatin for effective treatment. Therefore, using therapies that involve a combination of phytochemical or novel drug delivery system would be a novel treatment for cancer. Phytochemicals are plant-derived compounds that exhibit anti-cancer, anti-oxidative, anti-inflammatory properties and reduce side effects exerted by chemotherapeutics.Keywords
This publication has 102 references indexed in Scilit:
- Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-GlycoproteinPLOS ONE, 2012
- Genetic heterogeneity and cancer drug resistanceThe Lancet Oncology, 2012
- EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancerBMC Cancer, 2012
- Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cellsMolecular BioSystems, 2012
- Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt–GSK-3β–Cyclin D1 pathwayCancer Letters, 2010
- Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMycCancer Cell International, 2010
- DNA Damage, Mutagenesis, and DNA RepairJournal of Nucleic Acids, 2010
- The basics of epithelial-mesenchymal transitionJournal of Clinical Investigation, 2009
- The biology of ovarian cancer: new opportunities for translationNature Reviews Cancer, 2009
- Enhancing the efficacy of cisplatin in ovarian cancer treatment – could arsenic have a roleJournal of Ovarian Research, 2009